{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:50Z","timestamp":1789972130528,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004396","name":"Thailand Research Fund","doi-asserted-by":"crossref","award":["RTA 488-0007"],"award-info":[{"award-number":["RTA 488-0007"]}],"id":[{"id":"10.13039\/501100004396","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006733","name":"Commission on Higher Education","doi-asserted-by":"crossref","award":["CHE-RES-RG-49"],"award-info":[{"award-number":["CHE-RES-RG-49"]}],"id":[{"id":"10.13039\/501100006733","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.bbrc.2014.04.044","type":"journal-article","created":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T11:09:19Z","timestamp":1397819359000},"page":"580-585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues"],"prefix":"10.1016","volume":"447","author":[{"given":"Tanwarat","family":"Sanvoranart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aungkura","family":"Supokawej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pakpoom","family":"Kheolamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowalak","family":"U-pratya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuttha","family":"Klincumhom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirikul","family":"Manochantr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Methichit","family":"Wattanapanitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surapol","family":"Issaragrisil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2014.04.044_b0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bbrc.2014.04.044_b0010","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ecl.2012.04.006","article-title":"Pathophysiology of osteoporosis: new mechanistic insights","volume":"41","author":"Armas","year":"2012","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.bbrc.2014.04.044_b0015","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrendo.2013.17","article-title":"Postmenopausal hormone therapy: risks and benefits","volume":"9","author":"Rozenberg","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bbrc.2014.04.044_b0020","first-page":"435","article-title":"Osteoporosis \u2013 a current view of pharmacological prevention and treatment","volume":"7","author":"Das","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.bbrc.2014.04.044_b0025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11914-011-0065-0","article-title":"Effects of anti-osteoporosis medications on fracture healing","volume":"9","author":"Jorgensen","year":"2011","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bbrc.2014.04.044_b0030","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.amjmed.2008.12.005","article-title":"Osteonecrosis of the jaw and the role of bisphosphonates: a critical review","volume":"122","author":"Silverman","year":"2009","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bbrc.2014.04.044_b0035","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bbrc.2014.04.044_b0040","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2131\/jts.37.617","article-title":"Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (Human parathyroid hormone (1\u201334))","volume":"37","author":"Watanabe","year":"2012","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.bbrc.2014.04.044_b0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1756-8722-5-19","article-title":"Clinical applications of mesenchymal stem cells","volume":"5","author":"Wang","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2014.04.044_b0050","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/stem.572","article-title":"Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone","volume":"29","author":"Li","year":"2011","journal-title":"Stem Cells"},{"key":"10.1016\/j.bbrc.2014.04.044_b0055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10517-006-0115-2","article-title":"Differentiation potential of mesenchymal stem cells of different origin","volume":"141","author":"Musina","year":"2006","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.bbrc.2014.04.044_b0060","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1089\/scd.2007.0154","article-title":"Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells","volume":"17","author":"Barlow","year":"2008","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.bbrc.2014.04.044_b0065","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3181\/0712-RM-356","article-title":"Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue","volume":"233","author":"Rebelatto","year":"2008","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.bbrc.2014.04.044_b0070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (Velcadetrade mark) in the treatment of multiple myeloma","volume":"2","author":"Field-Smith","year":"2006","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.bbrc.2014.04.044_b0075","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2014.04.044_b0080","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/sj.leu.2403758","article-title":"High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation","volume":"19","author":"Shimazaki","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2014.04.044_b0085","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1172\/JCI16198","article-title":"Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro","volume":"111","author":"Garrett","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbrc.2014.04.044_b0090","first-page":"491","article-title":"Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice","volume":"118","author":"Mukherjee","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbrc.2014.04.044_b0095","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood-2008-08-174300","article-title":"Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin\/TCF signaling","volume":"113","author":"Qiang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2014.04.044_b0100","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2007-03-067710","article-title":"Myeloma bone disease and proteasome inhibition therapies","volume":"110","author":"Terpos","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2014.04.044_b0105","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.exphem.2009.04.004","article-title":"Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets","volume":"37","author":"Giuliani","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bbrc.2014.04.044_b0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbrc.2014.04.044_b0115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00277-011-1300-6","article-title":"In vitro vessel-forming capacity of endothelial progenitor cells in high glucose conditions","volume":"91","author":"Jiraritthamrong","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bbrc.2014.04.044_b0120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1034\/j.1600-0609.2000.90074.x","article-title":"Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma","volume":"64","author":"Abildgaard","year":"2000","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bbrc.2014.04.044_b0125","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2004.05084.x","article-title":"Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells","volume":"126","author":"Silvestris","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbrc.2014.04.044_b0130","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2014.04.044_b0135","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI28551","article-title":"Regulation of bone mass by Wnt signaling","volume":"116","author":"Krishnan","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbrc.2014.04.044_b0140","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2014.04.044_b0145","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bone.2007.12.006","article-title":"Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma","volume":"42","author":"Qiang","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bbrc.2014.04.044_b0150","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2141.2007.06829.x","article-title":"Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease","volume":"139","author":"Oyajobi","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbrc.2014.04.044_b0155","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br. J. Haematol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X14006858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X14006858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T18:16:07Z","timestamp":1589220967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X14006858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0006291X14006858"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2014.04.044","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2014.04.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}